Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 3/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2692741 | 1.00 | S1PR5 (0.47) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL2692744 | 1.00 | S1PR5 (0.47) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL2692748 | 1.00 | S1PR5 (0.47) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL3527474 | 0.86 | GRIN2B (0.45) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL5652849 | 0.82 | BRD4 (0.43) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL66496 | 0.82 | BRD4 (0.43) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL1014405 | 0.81 | FUCA1 (0.53) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL19063783 | 0.79 | GBA1 (0.51) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL19100375 | 0.79 | GBA1 (0.51) | S1PR5S1PR1FUCA1ACHEOPRM1 | |
| SCHEMBL1317322 | 0.79 | HRH3 (0.44) | S1PR5S1PR1FUCA1ACHEOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2024-09-26 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317705-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | S1PR5 881/4885S1PR1 761/4885FUCA1 2256/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | S1PR5 881/4885S1PR1 761/4885FUCA1 2256/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | S1PR5 881/4885S1PR1 761/4885FUCA1 2256/4885 |
| US-20100016400-A1 | AZABICYCLIC MUSCARINIC RECEPTOR ANTAGONISTS | CHRM3, CHRM5, CHRM2 | S1PR5 152/4885S1PR1 181/4885FUCA1 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.